Descrizione business
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| Prof. Dr. Dolores J. Schendel |
| Consiglio di amministrazione |
| Axel-Sven Malkomes |
| Consiglio di sorveglianza |
| Dr. Gerd Zettlmeissl, Antoinette Hiebeler-Hasner, Dr. Anthony Man, Dr. Frank Mathias, Dr. Keith Manchester, Ronald Scott |
Dati aziendali
| Name: |
Medigene AG |
| Indirizzo: |
Lochhamer Str. 11,D-82152 Planegg/Martinsried |
| Telefono: |
+49-89-200033-0 |
| Fax: |
+49-89-200033-2920 |
| E-mail: |
medigene@medigene.com
|
| Internet: |
www.medigene.com |
| Industria: |
Biotechnology |
| Settore: |
Biotechnology |
| Sub settore: |
Biotechnology |
| Fine dell'anno finanziario: |
31/12 |
| Flottante libero: |
85.50% |
| Data dell'IPO: |
30/06/2000 |
Rapporti con gli investitori
| Name: |
Dr. Anna Niedl |
| IR telefono: |
+49-89-200033-3301 |
| IR Fax: |
- |
| IR e-mail: |
investor@medigene.com
|
